With one foot already in the healthcare realm, multi-industry manufacturer Jabil is beefing up its biopharma bona fides with a transaction set to propel the company into the CDMO market.

Jabil saw strength in key end markets lead to quarterly results above its own expectations and that of Wall Street's. The electronics contract manufacturer logged net income of $100 million, or 88 ...